• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

FES 易累及肺腺癌并与雌激素受体阳性（ER+）乳腺癌相混淆。

FES avid pulmonary adenocarcinoma and confounding ER+ breast carcinoma.

作者信息

Abdelmoneim Yousif M, Lou Yanyan, Advani Pooja, Khoor Andras, Sharma Akash, Parent Ephraim E

机构信息

Department of Oncology, Mayo Clinic Florida, FL, 32224, USA.

Department of Pathology, Mayo Clinic Florida, FL, 32224, USA.

出版信息

Radiol Case Rep. 2024 Nov 14;20(1):801-804. doi: 10.1016/j.radcr.2024.10.114. eCollection 2025 Jan.

DOI:10.1016/j.radcr.2024.10.114
PMID:39624706
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11609104/
Abstract

Breast carcinomas are well known for expression of estrogen receptor (ER) however there are other malignancies that are also express ER, possibly confounding the diagnostic interpretation of 16α-[F]fluoro-17β-estradiol (FES; Cerianna GE HealthCare) in patients with both ER+ breast carcinomas and other malignancies. We present a case of a woman with prior history of both ER+ breast carcinoma and pulmonary adenocarcinoma with subsequent identification of an FES pulmonary nodule that was proven on histopathology to be consistent with an ER expressing pulmonary adenocarcinoma metastasis.

摘要

乳腺癌因表达雌激素受体（ER）而广为人知，然而，还有其他恶性肿瘤也表达ER，这可能会混淆16α-[F]氟-17β-雌二醇（FES；通用电气医疗集团的Cerianna）在同时患有ER阳性乳腺癌和其他恶性肿瘤患者中的诊断解读。我们报告了一例既往有ER阳性乳腺癌和肺腺癌病史的女性病例，随后发现一个FES肺结节，经组织病理学证实与表达ER的肺腺癌转移灶一致。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a743/11609104/9a6519110561/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a743/11609104/311aaa31bde3/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a743/11609104/9a6519110561/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a743/11609104/311aaa31bde3/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a743/11609104/9a6519110561/gr2.jpg

相似文献

1
FES avid pulmonary adenocarcinoma and confounding ER+ breast carcinoma.FES 易累及肺腺癌并与雌激素受体阳性（ER+）乳腺癌相混淆。
Radiol Case Rep. 2024 Nov 14;20(1):801-804. doi: 10.1016/j.radcr.2024.10.114. eCollection 2025 Jan.
2
Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16α-[F]Fluoro-17β-Estradiol PET.摘要：使用 16α-[F]氟-17β-雌二醇 PET 进行乳腺癌患者雌激素受体成像的 SNMMI 程序标准/EANM 实践指南。
J Nucl Med. 2024 Feb 1;65(2):221-223. doi: 10.2967/jnumed.123.266938.
3
Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.16α-18F-氟-17β-雌二醇正电子发射断层扫描全身特征在转移性乳腺癌中雌激素受体状态的评估：荟萃分析和纳入临床应用的建议。
Oncologist. 2020 Oct;25(10):835-844. doi: 10.1634/theoncologist.2019-0967. Epub 2020 May 15.
4
Clinical Validity of 16α-[F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.16α-[F]氟-17β-雌二醇正电子发射断层扫描/计算机断层扫描评估新诊断转移性乳腺癌雌激素受体状态的临床有效性。
J Clin Oncol. 2022 Nov 1;40(31):3642-3652. doi: 10.1200/JCO.22.00400. Epub 2022 May 18.
5
Intrapatient 16α-[F]Fluoro-17β-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.患者体内16α-[F]氟-17β-雌二醇PET异质性作为雌激素受体阳性转移性乳腺癌患者内分泌治疗反应和生存的预后因素
J Nucl Med. 2025 Feb 3;66(2):194-200. doi: 10.2967/jnumed.124.268984.
6
Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.2-[18F]氟-2-脱氧-D-葡萄糖和16α-[18F]氟-17β-雌二醇正电子发射断层扫描在乳腺癌中的应用：与雌激素受体状态及全身治疗反应的相关性
Clin Cancer Res. 1996 Jun;2(6):933-9.
7
Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.术前 PET 和雌激素受体配体在浸润性乳腺癌患者中的可行性和可预测性。
J Nucl Med. 2013 Oct;54(10):1697-702. doi: 10.2967/jnumed.112.113373. Epub 2013 Aug 22.
8
A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using F-FES PET/CT imaging.一项 1b 期研究，使用 F-FES PET/CT 成像评估 Elacestrant 治疗对转移性乳腺癌病灶中雌激素受体可用性和雌二醇与雌激素受体结合的影响。
Breast Cancer Res. 2020 Sep 11;22(1):97. doi: 10.1186/s13058-020-01333-3.
9
16α-18F-fluoro-17β-Fluoroestradiol (FES): Clinical Applications for Patients With Breast Cancer.16α-18F-氟-17β-氟雌二醇（FES）：乳腺癌患者的临床应用。
Semin Nucl Med. 2022 Sep;52(5):574-583. doi: 10.1053/j.semnuclmed.2022.03.002. Epub 2022 Apr 2.
10
F-FES Whole-Body Imaging Protocol for Evaluating Tumor Estrogen Receptor Status in Patients with Recurrent or Metastatic Breast Cancer.F-FES 全身成像方案用于评估复发性或转移性乳腺癌患者的肿瘤雌激素受体状态。
J Nucl Med Technol. 2023 Sep;51(3):188-193. doi: 10.2967/jnmt.122.265272. Epub 2023 Jul 11.

本文引用的文献

1
Estrogen, Estrogen Receptor and Lung Cancer.雌激素、雌激素受体与肺癌
Int J Mol Sci. 2017 Aug 5;18(8):1713. doi: 10.3390/ijms18081713.
2
Synthesis and Evaluation of the Estrogen Receptor β-Selective Radioligand 2-F-Fluoro-6-(6-Hydroxynaphthalen-2-yl)Pyridin-3-ol: Comparison with 16α-F-Fluoro-17β-Estradiol.雌激素受体β选择性放射性配体2-F-氟-6-(6-羟基萘-2-基)吡啶-3-醇的合成与评价：与16α-F-氟-17β-雌二醇的比较
J Nucl Med. 2017 Apr;58(4):554-559. doi: 10.2967/jnumed.116.180158. Epub 2016 Dec 1.
3
ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations.
雌激素受体β（ERβ）的定位影响了表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）对表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）患者的治疗效果。
Sci Rep. 2015 Jun 22;5:11392. doi: 10.1038/srep11392.
4
Estrogen signaling in lung cancer: an opportunity for novel therapy.肺癌中的雌激素信号：新型治疗的机会。
Cancers (Basel). 2012 Sep 25;4(4):969-88. doi: 10.3390/cancers4040969.
5
Synthesis and biological evaluation of two agents for imaging estrogen receptor β by positron emission tomography: challenges in PET imaging of a low abundance target.通过正电子发射断层扫描合成并评估两种用于雌激素受体 β 成像的试剂：低丰度靶标 PET 成像中的挑战。
Nucl Med Biol. 2012 Nov;39(8):1105-16. doi: 10.1016/j.nucmedbio.2012.05.011. Epub 2012 Jun 30.
6
Estrogen receptors, antiestrogens, and non-small cell lung cancer.雌激素受体、抗雌激素药物与非小细胞肺癌。
Biochemistry (Mosc). 2010 Dec;75(12):1421-7. doi: 10.1134/s0006297910120011.
7
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial.绝经后女性中雌激素加孕激素与肺癌（妇女健康倡议试验）：一项随机对照试验的事后分析
Lancet. 2009 Oct 10;374(9697):1243-51. doi: 10.1016/S0140-6736(09)61526-9. Epub 2009 Sep 18.
8
Synthesis and evaluation of aryl-substituted diarylpropionitriles, selective ligands for estrogen receptor beta, as positron-emission tomographic imaging agents.芳基取代的二芳基丙腈作为正电子发射断层成像剂的合成与评价，雌激素受体β的选择性配体
Bioorg Med Chem. 2009 May 1;17(9):3479-88. doi: 10.1016/j.bmc.2009.02.064. Epub 2009 Mar 9.
9
Estrogen receptor beta functions through nongenomic mechanisms in lung cancer cells.雌激素受体β通过非基因组机制在肺癌细胞中发挥作用。
Mol Endocrinol. 2009 Feb;23(2):146-56. doi: 10.1210/me.2008-0431. Epub 2008 Dec 23.
10
Synthesis of an estrogen receptor beta-selective radioligand: 5-[18F]fluoro-(2R,3S)-2,3-bis(4-hydroxyphenyl)pentanenitrile and comparison of in vivo distribution with 16alpha-[18F]fluoro-17beta-estradiol.一种雌激素受体β选择性放射性配体的合成：5-[18F]氟-(2R,3S)-2,3-双(4-羟基苯基)戊腈及其与16α-[18F]氟-17β-雌二醇的体内分布比较。
J Med Chem. 2005 Oct 6;48(20):6366-78. doi: 10.1021/jm050121f.